Capital Directions Investment Advisors’s Gilead Sciences GILD Stock Holding History

Capital Directions Investment Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-220	Closed	-$14K	–	223
2022 Q2	$14K	Sell	220 -33	-13%	-$2.04K	﹤0.01%	202
2022 Q1	$15K	Buy	+253	New	+$16.2K	﹤0.01%	215
2021 Q4	–	Sell	-1,220	Closed	-$85K	–	116
2021 Q3	$85K	Hold	1,220	–	–	0.03%	101
2021 Q2	$84K	Buy	+1,220	New	+$81.5K	0.03%	93
2021 Q1	–	Sell	-1,000	Closed	-$58K	–	235
2020 Q4	$58K	Hold	1,000	–	–	0.02%	105
2020 Q3	$63K	Buy	+1,000	New	+$69.3K	0.02%	93
2020 Q2	–	Sell	-1,000	Closed	-$75K	–	220
2020 Q1	$75K	Hold	1,000	–	–	0.03%	85
2019 Q4	$65K	Hold	1,000	–	–	0.02%	116
2019 Q3	$63K	Buy	+1,000	New	+$65.4K	0.02%	111
2018 Q3	–	Sell	-1,000	Closed	-$71K	–	174
2018 Q2	$71K	Buy	+1,000	New	+$70.6K	0.03%	59

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital Directions Investment Advisors's GILD Position: Q3 2022 in Review

Capital Directions Investment Advisors sold out of Gilead Sciences (GILD) in Q3 2022, closing a stake of 220 shares — an estimated $14K sold.

Capital Directions Investment Advisors first reported a position in GILD in Q2 2018 and held it in 10 quarters. The position peaked at $85K in Q3 2021. 1,603 funds tracked by Wall St. Rank hold GILD as of Q3 2022.

Capital Directions Investment Advisors reported no remaining Gilead Sciences position as of Q3 2022 after selling out during the quarter.
Capital Directions Investment Advisors sold 220 Gilead Sciences shares in Q3 2022, an estimated $14K.
Capital Directions Investment Advisors first reported a position in Gilead Sciences in Q2 2018 and held it in 10 quarters.
Capital Directions Investment Advisors's Gilead Sciences position peaked at $85K in Q3 2021.
1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.

Based on Capital Directions Investment Advisors's 13F filing for Q3 2022, filed 2 Nov 2022.